Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07

Full metadata record
DC Field Value Language
dc.contributor.authorKim, Seung Tae-
dc.contributor.authorKim, Sun Young-
dc.contributor.authorLee, Jeeyun-
dc.contributor.authorYun, Seong Hyeon-
dc.contributor.authorKim, Hee Cheol-
dc.contributor.authorLee, Woo Yong-
dc.contributor.authorKim, Tae Won-
dc.contributor.authorHong, Yong Sang-
dc.contributor.authorLim, Seok-Byung-
dc.contributor.authorBaek, Ji Yeon-
dc.contributor.authorOh, Jae Hwan-
dc.contributor.authorAhn, Joong Bae-
dc.contributor.authorShin, Sang Joon-
dc.contributor.authorHan, Sae-Won-
dc.contributor.authorKim, Seong Geun-
dc.contributor.authorKang, Seok Yun-
dc.contributor.authorSym, Sun Jin-
dc.contributor.authorZang, Dae Young-
dc.contributor.authorKim, Yeul Hong-
dc.contributor.authorChoi, In Sil-
dc.contributor.authorKang, Jung Hun-
dc.contributor.authorKim, Min-Ji-
dc.contributor.authorPark, Young Suk-
dc.date.accessioned2024-11-15T19:22:34Z-
dc.date.available2024-11-15T19:22:34Z-
dc.date.issued2022-11-20-
dc.identifier.issn0732-183X-
dc.identifier.issn1527-7755-
dc.identifier.urihttps://scholar.korea.ac.kr/handle/2021.sw.korea/190354-
dc.description.abstractPURPOSE The combination of oxaliplatin and fluoropyrimidine for 6 months is one of the standard options for adjuvant therapy for high-risk stage II and III colorectal cancers (CRCs). The optimal duration of oxaliplatin to diminish neurotoxicity without compromising efficacy needs to be clarified. PATIENTS AND METHODS This open-label, randomized, phase III, noninferiority trial randomly assigned patients with high-risk stage II and III CRC to 3 and 6 months of oxaliplatin with 6 months of fluoropyrimidine groups (3- and 6-month arms, respectively). The primary end point was disease-free survival (DFS), and the noninferiority margin was a hazard ratio (HR) of 1.25. RESULTS In total, 1,788 patients were randomly assigned to the 6-month (n = 895) and 3-month (n = 893) arms, and 83.6% in the 6-month arm and 85.7% in the 3-month arm completed the treatment. The neuropathy rates with any grade were higher in the 6-month arm than in the 3-month arm (69.5% v 58.3%; P < .0001). The 3-year DFS rates were 83.7% and 84.7% in the 6-month and 3-month arms, respectively, with an HR of 0.953 (95% CI, 0.769 to 1.180; test for noninferiority, P = .0065) within the noninferiority margin. Among patients with stage III CRC treated by capecitabine plus oxaliplatin, the 3-year DFS of the 3-month arm was noninferior as compared with that of the 6-month arm with an HR of 0.713 (95% CI, 0.530 to 0.959; P = .0009). However, among patients with high-risk stage II and stage III CRC treated by infusional fluorouracil, leucovorin, and oxaliplatin, the noninferiority of the 3-month arm compared with the 6-month arm was not proven. CONCLUSION This study suggests that adding 3 months of oxaliplatin to 6 months of capecitabine could be considered an alternative adjuvant treatment for stage III CRC (ClinicalTrials.gov identifier: ). (C) 2022 by American Society of Clinical Oncology-
dc.language영어-
dc.language.isoENG-
dc.publisherLIPPINCOTT WILLIAMS & WILKINS-
dc.titleOxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07-
dc.typeArticle-
dc.publisher.location미국-
dc.identifier.doi10.1200/JCO.21.02962-
dc.identifier.scopusid2-s2.0-85142401178-
dc.identifier.wosid000886149800011-
dc.identifier.bibliographicCitationJOURNAL OF CLINICAL ONCOLOGY, v.40, no.33, pp 3868 - +-
dc.citation.titleJOURNAL OF CLINICAL ONCOLOGY-
dc.citation.volume40-
dc.citation.number33-
dc.citation.startPage3868-
dc.citation.endPage+-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaOncology-
dc.relation.journalWebOfScienceCategoryOncology-
dc.subject.keywordPlusWEEKLY BOLUS FLUOROURACIL-
dc.subject.keywordPlusPHASE-III TRIAL-
dc.subject.keywordPlusCOLORECTAL-CANCER-
dc.subject.keywordPlusCHEMOTHERAPY-
dc.subject.keywordPlusLEUCOVORIN-
dc.subject.keywordPlusDURATION-
dc.subject.keywordPlusSURVIVAL-
dc.subject.keywordPlusEFFICACY-
dc.subject.keywordPlusSAFETY-
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE